| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.30.12.1326 |
| P953 | full work available at URL | http://journals.lww.com/00006114-198012000-00015 |
| P698 | PubMed publication ID | 6109265 |
| P50 | author | Yves Agid | Q3573439 |
| P2093 | author name string | F. Javoy-Agid | |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| dopamine | Q170304 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 1326-1330 | |
| P577 | publication date | 1980-12-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Is the mesocortical dopaminergic system involved in Parkinson disease? | |
| P478 | volume | 30 |
| Q30446663 | "Perestroika" in the basal forebrain: opening the border between neurology and psychiatry |
| Q31919970 | A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes |
| Q48308472 | A specific shifting deficit in Parkinson's disease: a reversal shift of consistent stimulus-response mappings |
| Q48931126 | Action of tianeptine on focalization of attention in cat. |
| Q92163379 | Activating dopamine D2 receptors reduces brown adipose tissue thermogenesis induced by psychological stress and by activation of the lateral habenula |
| Q33619721 | Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease |
| Q35222898 | Amine Accumulation: A Possible Precursor of Lewy Body Formation in Parkinson's Disease |
| Q37887678 | Anhedonia in Parkinson's disease: a systematic review of the literature. |
| Q32090982 | Antipsychotic medications and the elderly: effects on cognition and implications for use. |
| Q81554190 | Are neuropsychological tests useful in screening for the genetic risk of Parkinson's disease? |
| Q48614669 | Attenuation of preparatory activity for reaching movements by a D1-dopamine antagonist in the monkey premotor cortex |
| Q52017685 | Automatic orienting of visuospatial attention in Parkinson's disease. |
| Q45303735 | Basal ganglia disease |
| Q38438683 | Basal ganglia dysfunction, working memory, and sentence comprehension in patients with Parkinson's disease |
| Q44627789 | Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice |
| Q37491183 | Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. |
| Q38351038 | Biochemistry of Parkinson's disease 28 years later: a critical review |
| Q35684600 | Brain systems underlying susceptibility to helplessness and depression |
| Q36275740 | CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease |
| Q54996309 | Calbindin-D 28kD immunofluorescence in ventral mesencephalic neurons labeled following injections of Fluoro-Gold in nucleus accumbens subterritories: inverse relationship relative to known neurotoxin vulnerabilities |
| Q48866743 | Caudate nucleus area in drug-induced parkinsonism |
| Q31172552 | Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection |
| Q40715939 | Centrencephalic theory, the general learning system, and subcortical dementia |
| Q44325367 | Cerebral blood flow and oxygen metabolism in rett syndrome |
| Q38444112 | Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients |
| Q41135565 | Chronic treatment with D1 and D2 dopamine receptor agonists: combined treatments interact to differentially affect brain levels of monoamines |
| Q28066313 | Classification and Characteristics of Pain Associated with Parkinson's Disease |
| Q72172733 | Clozapine therapeutic plunge in patient with Parkinson's disease |
| Q33629294 | Cognitive concomitants of dopamine system stimulation in parkinsonian patients |
| Q49157792 | Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex |
| Q47418267 | Computational Dissection of Dopamine Motor and Motivational Functions in Humans. |
| Q39279561 | Confusion, dementia and anticholinergics in Parkinson's disease |
| Q41960633 | Cortical activity in Parkinson's disease during executive processing depends on striatal involvement |
| Q35475386 | Counterfactual cognitive deficit in persons with Parkinson's disease |
| Q58255356 | Decline and fall: A biological, developmental, and psycholinguistic account of deliberative language processes and ageing |
| Q33629400 | Defective concept formation in parkinsonians is independent from mental deterioration |
| Q48498482 | Dementia in Parkinson's disease: possible specific involvement of the frontal lobes |
| Q48701471 | Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases |
| Q39480484 | Dementia in movement disorders. |
| Q34939816 | Dementia, the fate of brain? Neuropathological point of view |
| Q39450868 | Depression in Parkinson's disease. Pharmacological characteristics and treatment |
| Q38214419 | Differential aspects of cognitive impairment in patients suffering from Parkinson's and Alzheimer's disease: a neuropsychological evaluation |
| Q26801298 | Differential effects of dopamine-directed treatments on cognition |
| Q52057332 | Distractibility in early Parkinson's disease. |
| Q64785695 | Distribution of Catecholamines in the Ventral Mesencephalon of Human Brain, with Special Reference to Parkinson's Disease |
| Q44186005 | Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. |
| Q48738961 | Dopamine visualized in the basal ganglia of living man. |
| Q42205368 | Dopaminergic and cholinergic lesions in progressive supranuclear palsy |
| Q52019986 | Education and cognitive decline in Parkinson's disease: a study of 102 patients. |
| Q42220053 | Effect of levodopa treatment on contrast sensitivity in Parkinson's disease |
| Q50643736 | Effect of unilateral and bilateral lesions of caudate-putamen on immune response in the rat. |
| Q53318451 | Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. |
| Q33967306 | Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. |
| Q48892074 | Enkephalin dipeptidyl carboxypeptidase (enkephalinase) activity: selective radioassay, properties, and regional distribution in human brain |
| Q71609493 | Evaluation of olfactory function by topographic EEG analysis in patients with Parkinson's disease |
| Q21090466 | Executive dysfunction in Parkinson's disease and timing deficits |
| Q48553322 | Features of brain atrophy in Parkinson's disease. A CT scan study |
| Q39754744 | Frontostriatal cognitive staging in Parkinson's disease |
| Q38088371 | Functional neuroimaging in Parkinson's disease |
| Q41552501 | Glycine Receptors in the Human Substantia Nigra as Defined by [3H]Strychnine Binding |
| Q38214420 | Hypothalamic compensatory mechanisms in Parkinson's disease |
| Q52123664 | Impaired attention modulation of the blink reflex R3 component in Parkinson's disease: a non-task warning paradigm study. |
| Q40648997 | Improvement in word-fluency performance in Parkinson's disease by administration of electromagnetic fields |
| Q52056215 | Improvement in word-fluency performance in patients with multiple sclerosis by electromagnetic fields. |
| Q48238959 | Intracerebral grafting of dopamine neurons. Experimental basis for clinical trials in patients with Parkinson's disease. |
| Q73320609 | Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats |
| Q31802953 | Investigation of non-linear properties of multichannel EEG in the early stages of Parkinson's disease. |
| Q72476671 | Is the blood-brain barrier really intact in portal-systemic encephalopathy? |
| Q42164140 | Levodopa-induced ocular dyskinesias in Parkinson's disease |
| Q53257864 | Lewy bodies, a misleading marker for Parkinson's disease? |
| Q64990193 | Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration. |
| Q35069025 | MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain. |
| Q33628446 | Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse |
| Q35998652 | Memory systems analyses of mnemonic disorders in aging and age-related diseases |
| Q64785437 | Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease |
| Q64785506 | Methionine-enkephalin deficiency in brains of patients with Parkinson's disease |
| Q52498619 | Micro topography of Tyrosine Hydroxylase, Glutamic Acid Decarboxylase, and Choline Acetyltransferase in the Substantia Nigra and Ventral Tegmental Area of Control and Parkinsonian Brains |
| Q37320970 | Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells |
| Q41787776 | Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study |
| Q41723925 | Motor and cognitive aspects of motor retardation in depression |
| Q43564955 | Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease |
| Q46475659 | Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. |
| Q40090864 | Multiple dopamine receptors and behavior |
| Q41690270 | Neuroanatomy of the basal ganglia |
| Q31871480 | Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound |
| Q38764493 | Neuropsychiatry of corticosubcortical relations Aphasia and depression as paradigms |
| Q69779690 | Neuropsychological similarities in lateralized parkinsonism |
| Q45098438 | Neuroradiological covariates of drug-induced parkinsonism and tardive dyskinesia in schizophrenia |
| Q37167222 | Neurotransmitter Receptors in Human Brain Diseases |
| Q46291726 | Nicotinic-dopaminergic relationships and radial-arm maze performance in rats |
| Q43125929 | Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation |
| Q50928726 | Organization of the ascending projections from the ventral tegmental area: A multiple fluorescent retrograde tracer study in the rat |
| Q64869820 | Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease |
| Q36186763 | Parkinson's disease dementia: a neural networks perspective |
| Q40191579 | Parkinson's disease in 1984: an update. |
| Q48857336 | Pathological basis for neurotransmitter changes in Parkinson's disease |
| Q48853024 | Patients with early Parkinson's disease are not impaired on spatial orientating of attention |
| Q48475590 | Perception of emotional speech in Parkinson's disease |
| Q33790219 | Pragmatic comprehension deficit in Parkinson's disease |
| Q36483541 | Prefrontal D1 dopamine signaling is required for temporal control |
| Q38111335 | Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease |
| Q51431445 | Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. |
| Q37885421 | Probing basal ganglia functions by saccade eye movements |
| Q39728822 | Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality |
| Q39433401 | Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions |
| Q46169445 | Psychotic and compulsive symptoms in Parkinson's disease. |
| Q35779329 | Psychotic symptoms in Parkinson's disease: pathophysiology and management |
| Q48280336 | Rapid improvement of visuoperceptive functions by picoTesla range magnetic fields in patients with Parkinson's disease |
| Q48830484 | Reduced ACTH/cortisol responses to naloxone in men with Parkinson's disease |
| Q37364825 | Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease |
| Q33622814 | Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations |
| Q28081107 | Regulation of dopamine system responsivity and its adaptive and pathological response to stress |
| Q48192857 | Relation of “Sense Of Self” to Executive Function Performance in Parkinson's Disease |
| Q69227577 | Repeated imipramine enhances sensitivity of the brain dopaminergic system related to exploratory behavior |
| Q51997893 | Reversal of cognitive impairment in an elderly parkinsonian patient by transcranial application of picotesla electromagnetic fields. |
| Q33985023 | Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease |
| Q44467578 | SSRIs in the treatment of depression in Parkinson's disease |
| Q48227807 | Selective attention is impaired in amyotrophic lateral sclerosis--a study of event-related EEG potentials |
| Q48939047 | Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease |
| Q30498974 | Semantic processing deficits in patients with Parkinson's disease: degraded representation or defective retrieval? |
| Q48308843 | Sensitivity to ageing of the limbic dopaminergic system: a review |
| Q48422836 | Sleep in Parkinson syndromes |
| Q48495394 | Spared error-related potentials in mild to moderate Parkinson's disease |
| Q30895929 | Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease |
| Q52511678 | Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism. |
| Q64863585 | Sympathetic skin response asymmetry in early stage idiopathic Parkinson's disease |
| Q48307955 | Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization |
| Q64039646 | The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson's Disease |
| Q38562348 | The Vulnerable Ventral Tegmental Area in Parkinson's Disease |
| Q38424137 | The basal ganglia and semantic engagement: potential insights from semantic priming in individuals with subcortical vascular lesions, Parkinson's disease, and cortical lesions |
| Q39421226 | The concept of subcortical and cortical dementia: another look |
| Q33593378 | The contribution of neuroimaging for the study of cognitive deficits in Parkinson's disease |
| Q48835443 | The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent |
| Q52060166 | The effects of picoTesla range magnetic fields on perceptual organization and visual memory in parkinsonism. |
| Q37556320 | The etiology of depression in Parkinson's disease patients |
| Q36925932 | The late positive potential, emotion and apathy in Parkinson's disease |
| Q46914441 | The long-term effects of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) on cognitive performance in rats. |
| Q41178359 | The relationship of negative schizophrenia to parkinsonism |
| Q52024220 | The role of D1-dopamine receptors in working memory-guided movements mediated by frontal cortical areas. |
| Q37841542 | The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review |
| Q36089350 | Treatment of behavioural symptoms and dementia in Parkinson's disease |
| Q64777619 | Up-regulation of tyrosine hydroxylase mRNA in a sub-population of A10 dopamine neurons in Parkinson's disease |
| Q26767268 | What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease? |
| Q81651034 | Working memory |
| Q48482872 | Xenon contrast CT-CBF measurements in parkinsonism and normal aging |
| Q52068190 | [99mTc]-HM-PAO SPECT in Parkinson's disease. |
| Q51978301 | [Comparison study of executive functions in Parkinson's disease and degenerative cerebellar disease's patients]. |
Search more.